Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar details- 2023
-
26 min
1. Planning and response to COVID-19: lessons from China and South-East Asia- Prof. Annelies Wilder-Smith
- 2022
-
12 min
2. The emergence of the SARS-CoV-2 Omicron variant- Prof. Emma Thomson
-
14 min
3. How is Omicron different?- Prof. Emma Thomson
- 2021
-
14 min
-
15 min
5. Potential of ‘long-COVID’ in triggering chronic co-pathologies- Dr. İmdat Eroğlu
-
8 min
6. SARS-CoV-2 monoclonal antibody testing in vivo- Prof. Michael Diamond
-
17 min
7. mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals- Prof. E. John Wherry
-
12 min
8. SARS-CoV-2 variants: implications for immunity and vaccine development- Prof. Danny Altmann
-
14 min
-
11 min
10. SARS-COV-2 human monoclonal antibody therapy update- Prof. James Crowe
-
12 min
11. Emergence of blood clotting disorders resulting from COVID vaccines inoculations- Prof. Dr. Sabine Eichinger
-
9 min
12. SARS-CoV-2 evolution within and between individuals- Prof. Katia Koelle
-
10 min
13. Identifying SARS-CoV-2 proteases- Prof. Dr. Christa E. Müller
- Prof. Dr. Michael Gütschow
-
20 min
14. Genetic surveillance and the emergence of SARS-CoV-2 variants- Prof. Emma Thomson
-
16 min
15. The COVID-19 outbreak: April 2021 update- Prof. Jonathan Temte
-
15 min
16. ABO blood groups and SARS-CoV-2 susceptibility- Dr. Sean Stowell
-
20 min
17. Impact of COVID-19 on neuropsychiatric disorders and mental health- Prof. Anthony David
-
20 min
18. The immune system response to the SARS-CoV-2 virus: March 2021 update- Prof. Paul Klenerman
-
6 min
-
12 min
-
13 min
-
18 min
-
17 min
23. SARS-CoV-2 vaccine rollout campaigns- Prof. Luis Graca
-
11 min
-
15 min
25. Interspecies transmission of SARS-CoV-2- Dr. Dalan Bailey
-
12 min
26. Complement activation in COVID-19- Prof. Jeffrey Laurence
-
9 min
27. Human movement patterns and local spread of COVID-19- Prof. Ben Cowling
-
10 min
28. SARS-CoV-2 mutations: phenotypes and implications for vaccine development- Prof. David Montefiori
- 2020
-
18 min
29. The immune system response to the SARS-CoV-2 virus: December 2020 update- Prof. Paul Klenerman
-
20 min
30. Triage and end of life care planning in COVID-19- Prof. Robin Taylor
-
14 min
31. Natural killer cells as COVID-19 therapy- Dr. Philippa Kennedy
-
13 min
32. Update on the SNG001 drug, an INFβ therapy for COVID-19- Prof. Stephen Holgate
-
15 min
-
10 min
34. Identification of a new coronavirus-specific RNA export protein complex- Dr. Montse Bárcena-Martin
-
17 min
35. The neurological symptoms of COVID-19- Dr. Michael Zandi
-
12 min
36. Imperial College London’s saRNA Vaccine - COVAC1- Dr. Katrina Pollock
-
15 min
37. Interferon-α2b as a therapy for COVID-19- Prof. Eleanor N. Fish
-
11 min
38. Potential long-term health effects of a SARS-CoV-2 infection- Prof. Danny Altmann
-
12 min
39. The COVID-19 coronavirus outbreak: October 2020 update- Prof. Jonathan Temte
-
9 min
-
16 min
41. Rheumatic diseases and COVID-19- Dr. Zachary Wallace
-
17 min
42. The cardiovascular complications of SARS-CoV-2 infection- Prof. Srihari Naidu
-
20 min
43. Medical wearable devices for tracking symptoms of COVID-19- Prof. John Rogers
-
21 min
44. Risk of re-emergence of COVID-19 after exit from lockdown- Dr. Leonardo Lopez
-
16 min
45. The evolutionary origin of SARS-CoV-2- Dr. Feng Gao
-
15 min
46. Predicting COVID-19 outbreaks by measuring SARS-CoV-2 RNA in sewage sludge- Prof. Jordan Peccia
-
12 min
47. Approaches for elucidating genetic susceptibility to SARS-CoV-2- Dr. Kenneth Baillie
-
22 min
48. The immune system response to the SARS-CoV-2 virus: July 2020 update- Prof. Paul Klenerman
-
22 min
49. The impact of COVID-19 in the elderly and in care homes- Dr. David Strain
-
19 min
50. Human challenge trials for vaccines against COVID-19- Prof. Peter Smith
-
9 min
51. The development of SARS-CoV-2 vaccines- Prof. Peter Hotez
-
15 min
52. Convalescent plasma therapy as a treatment for COVID-19- Dr. Manu Shankar-Hari
-
12 min
53. Remdesivir COVID-19 clinical trial- Prof. Mahesh Parmar
-
17 min
54. Nanotechnologies in the fight against coronaviruses- Prof. Sabine Szunerits
-
15 min
55. The COVID-19 coronavirus outbreak: May 2020 update- Prof. Jonathan Temte
-
10 min
56. INFβ therapy for COVID-19: the new SNG001 drug- Prof. Stephen Holgate
-
12 min
57. Strategies for exiting the lockdown- Prof. David McCoy
-
17 min
58. SARS-CoV-2 human monoclonal antibody therapy- Prof. James Crowe
-
8 min
59. An FDA approved salivary test for SARS-CoV-2 infection- Prof. Andrew Brooks
-
15 min
60. Development of an intranasal vaccine for SARS-CoV-2- Dr. Scot Roberts
-
13 min
61. The immune system response to the SARS-CoV-2 virus: an update- Prof. Paul Klenerman
-
8 min
62. A novel AIOD-CRISPR system for diagnosis of SARS-CoV-2- Prof. Changchun Liu
-
20 min
63. Development of PRO-140 (Leronlimab) as a treatment for COVID-19- Dr. Jacob Lalezari
-
16 min
64. COVID-19 epidemiology and potential treatments: follow up interview- Prof. Ralph Baric
-
12 min
65. SARS-CoV-2 vaccine development: where are we now?- Prof. Gary Kobinger
-
13 min
66. SARS-CoV-2: What we need to know and possible future therapies- Prof. Stanley Perlman
-
8 min
67. SARS-CoV-2 vaccine: current biological targets and considerations- Dr. Adolfo Garcia-Sastre
-
20 min
68. The current understanding of the biology of the SARS-CoV-2 virus- Prof. Peter Palese
-
16 min
-
17 min
70. The immune system response to the SARS-CoV-2 virus- Prof. Paul Klenerman
-
9 min
71. SARS-CoV-2 vaccine development- Prof. Stanley Plotkin
-
12 min
72. The COVID-19 outbreak: an update on the SARS-CoV-2 virus- Prof. Ralph Baric
-
14 min
73. The COVID-19 coronavirus outbreak: a current view- Prof. Jonathan Temte
-
17 min
74. The COVID-19 coronavirus outbreak: March 2020 update- Prof. Jonathan Temte
Topics Covered
- More precise estimate of the mortality rate
- What is the actual proportion of infected patients?
- Why does the mortality rate vary so much between countries?
- ‘Infectious dose’ or ‘number of viruses’ versus ‘viral load’
- Recent clinical trial results for SARS-2 treatments and vaccines
- Current clinical trials in Europe and the US
Biography
Ralph Baric is Professor of Microbiology and Immunology at the School of Medicine and Professor of Epidemiology at Gillings School of Global Public Health at the University of North Carolina, Chapel Hill. Dr. Baric’s research specializes in coronaviruses and emerging infections such as Zika virus. Most of the research in the Baric Lab uses coronaviruses as models to study the genetics of RNA virus transcription, replication, persistence and cross-species transmission. In 2017, Dr. Baric was included in the Clarivate Analytics’ Highly Cited Researchers list, which recognizes researchers from around the world who publish the most widely cited papers in their field.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Baric, R. (2020, April 20). COVID-19 epidemiology and potential treatments: follow up interview [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 9, 2025, from https://doi.org/10.69645/EJDU8552.Export Citation (RIS)
Publication History
- Published on April 20, 2020
Financial Disclosures
- Prof. Ralph Baric has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
COVID-19 epidemiology and potential treatments: follow up interview
Published on April 20, 2020
16 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
Quiz
Disclaimer: This quiz is intended for learning assessment purposes only and does not grant any certification or credit.
If you are interested in getting a certificate for watching the talk, follow the instructions in this talk's Accreditation Information (where available.)